Radiation oncologist perceptions of therapeutic cannabis use among cancer patients

• Published in: Supportive care in cancer 2021-10, Vol.29 (10), p.5991-5997
• Main Authors: Novak, Jennifer, Liu, Jason, Zou, Xiaoke, Abuali, Tariq, Vazquez, Jessica, Kalash, Ronny, Evans, Brett, Loscalzo, Matthew J., Sun, Virginia, Brower, Jeffrey, Amini, Arya
• Format: Article
• Language: English
• Subjects: Analysis; Attitudes; Cancer; Cancer patients; Care and treatment; Health aspects; Medical marijuana; Medicine; Medicine & Public Health; Nursing; Nursing Research; Oncology; Original Article; Pain Medicine; Patient safety; Physicians; Radiation; Radiation therapy; Rehabilitation Medicine; Side effects
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-021-06160-6

Introduction Cancer patients are increasingly incorporating medical marijuana into the management of treatment-related side effects. Currently however, data is limited regarding the risks and benefits of therapeutic cannabis for cancer patients. We sought to characterize radiation oncologists’ practices and opinions regarding therapeutic cannabis via a nationwide survey. Materials and methods An anonymous survey was distributed via email to 873 radiation oncologists in the American Society for Radiation Oncology member database. Radiation oncologists were asked their opinions and practices regarding the use of therapeutic cannabis for their patients. Bivariate analyses of potential predictors for responses were conducted using standard statistical techniques. Results One hundred seven radiation oncologists completed the survey. According to the survey, 36% of respondents would recommend therapeutic cannabis to their patients to mitigate treatment toxicity. Physicians practicing in states where medical marijuana is legal were more likely to recommend it compared to physicians working in states that have not legalized medical marijuana (OR = 3.79, 1.19–12.1, p = 0.01). Seventy-one percent of respondents reported therapeutic cannabis as being effective at least some of the time for managing treatment-related toxicities. Fifty-eight percent of physicians reported lacking sufficient knowledge to advise patients regarding therapeutic cannabis, while 86% of respondents were interested in learning more about therapeutic cannabis for cancer patients. Conclusions Although a majority of radiation oncologists believe there are benefits to therapeutic cannabis, many are hesitant to recommend for or against its use. Radiation oncologists appear to be interested in learning more about how therapeutic cannabis may play a role in their patients’ care.